Clinical Trial Update: Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting on the efficacy and safety of two doses of AQX-1125 in subjects with interstitial cystitis and bladder pain syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Pain Syndrome
• Interstitial Cystitis

Drugs mentioned

• AQX-1125

Snippet

Sponsor: Aquinox Pharmaceuticals (Canada) Inc. | Conditions: Interstitial Cystitis, Bladder Pain Syndrome | Phase 3 | Status: UNKNOWN